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Protective immunity relies upon differentiation of T cells into the appropriate subtype
required to clear infections and efficient effector T cell localization to antigen-rich tissue.
Recent studies have highlighted the role played by subpopulations of tissue-resident
memory (TRM) T lymphocytes in the protection from invading pathogens. The intestinal
mucosa and associated lymphoid tissue are densely populated by a variety of resident
lymphocyte populations, including αβ and γδ CD8+ intraepithelial T lymphocytes (IELs)
and CD4+ T cells. While the development of intestinal γδCD8+ IELs has been extensively
investigated, the origin and function of intestinal CD4+ T cells have not been clarified. We
report that CCR9 signals delivered during naïve T cell priming promote the differentiation
of a population of α4β
+
7 IFN-γ-producing memory CD4
+ T cells, which displays a
TRM molecular signature, preferentially localizes to the gastrointestinal (GI) tract and
associated lymphoid tissue and cannot be mobilized by remote antigenic challenge. We
further show that this population shapes the immune microenvironment of GI tissue, thus
affecting effector immunity in infection and cancer.
Keywords: chemokine, memory T cell differentiation, tissue resident cells, T helper (TH) 1 immunity, tissue
microenvironment
INTRODUCTION
Immune surveillance of the gastrointestinal (GI) tract is conventionally thought to depend on the
generation of a sizable cohort of recirculating α4β
high
7 memory T cells, which become able to access
the gut parenchyma and gut–associated lymphoid tissue (GALT).
The gut wall is densely populated by a variety of resident immune cells required for effective
immune responses against pathogens, while allowing coexistence with commensals and preventing
autoimmunity. For example, intraepithelial αβ and γδ CD8+ T lymphocytes (IELs) reside within
the intestinal epithelial layer provide a first line of defense at this extensive barrier (1). A substantial
cohort of memory CD4+ T cells is also present in the intestinal wall, particularly in the lamina
propria (LP) (2). Most of these cells display a Th1 phenotype in mice and humans (3–5). LP
CD4+ T cells also bear a distinctive homing phenotype, including co-expression of α4β7 and CCR9
(6). While the ontogenesis of TCR-αβ/γδ CD8αα intraepithelial T lymphocytes (IELs) has been
extensively investigated (7), the origin and function of this CD4+ T cell subset remain unclear (8).
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Tissue-derived factors play a key role in the differentiation of T
cells that populate non-lymphoid tissue, including tissue-resident
memory (TRM) T cells, which arise during priming, reside long-
term in tissues and play a key role in local protection from
re-infections (9). For example, the CXC-chemokine receptor 3
(CXCR3) is required for the localization of effector T cells to
the epidermis and for subsequent TRM cell differentiation (10).
Similarly, CXCR3 is instrumental for the localization of effector
T cells to the lung epithelium (11, 12). In the intestine, genetic
deletion of CCL25 or its receptor CCR9 results in depletion of
IELs (13, 14), which was attributed to impaired ability of these T
cells to localize to the gut wall. CCL25 expression is enhanced
in inflamed intestine (15), suggesting that its availability in
GALT increases during immune activation and the generation of
immunological memory.
Based on these observations, we have investigated the
contribution of the CCR9-CCL25 axis to the generation and
function of CD4+ T cell-mediated immunological memory in
the intestine and associated lymphoid tissue. We show that
CCR9 signals during priming promote the development of a
Th1 population with features of TRM cell which regulates the
local immune environment and protective responses against GI
infections and tumors.
MATERIALS AND METHODS
Mice
Mice were used at the age of 7–11 weeks. C57BL/6 mice
were purchased from Charles River (UK). Female Marilyn
mice, bearing a transgenic TCR specific for the male
minor transplantation antigen HY peptide epitope Dby
(NAGFNSNRANSSRSS) and restricted by H2-Ab molecules,
have been previously described (16). In this study, Marilyn-
Rag2−/− mice obtained by backcrossing for nine generations
were used. ccl25−/− and ccr9−/− mice have been previously
described (13, 14). OT-II mice, bearing a transgenic TCR
specific for the ovalbumin peptide epitope OVA323−339
(ISQAVHAAHAEINEAGR) and restricted by H2-Ab molecules,
have been previously described (4). All the in vivo experiments
were conducted under the Home Office regulation and approved
by the local Ethics Committee.
Reagents
The cell linker PKH26 was purchased from Sigma-Aldrich
and used at 2µM. CFSE was purchased from Invitrogen and
used at 4µM. Dylight 488 Amine-Reactive Dye and Kits
were purchased from Thermo Scientific. In proliferation assays
measuring CFSE dilution by flow cytometry, the average number
of cell divisions that a cell in the original population has
undergone (Division Index) was measured using Flowjo 7.6
(TreeStar Inc).
The chemokine CCL25 was purchased from PeproTech EC
Ltd. The Dby peptide was purchased fromCambridge Bioscience.
Pertussis Toxin was purchased from Sigma. 3,7-dimethyl-2,6-
octadienal (Citral) was purchased from Sigma and used in the
co-cultures at a working concentration of 0.1µM.
Antibodies
Naïve T cells were purified by immunomagnetic
negative selection using EasySepTM. Mouse Naïve T
cells Isolation Kits (Stemcell Technologies) according to
manufacturer’s instructions.
The affinity-purified polyclonal goat anti-mouse CCR9
Ab was purchased from Novus Biological (NB100-
708). The immunogen for this antibody is the peptide
IPGMFDDFSYDSTASTDDYMNLNFSSFF, corresponding
to amino acids 10–37 of Mouse CCR9. Its biological activity has
not been described.
For immunohistochemistry, the following antibodies were
used: Armenian hamster anti-mouse CD11c (1:50, clone N418,
BioLegend), polyclonal Rat anti-mouse CD31 Antibody (clone
MEC 13.3, Cat No: 102502, BioLegend), rat anti-mouse CCL25
Ab (clone 89827, R&D), Rat anti-mouse MadCAM-1 (clone:
MECA-367, Cat No: 16-5997-85, ThermoFisher). Alexa Fluor
555-conjugated Goat Anti-Rat IgG (H+L) (1:100), and Alexa
Fluor 488-conjugated Goat Anti-Hamster IgG (H+L) (1:100)
were purchased from Invitrogen/Life Technologies.
All flow cytometry antibodies were used at 1:200 dilution
unless otherwise specified. APC-conjugated anti-mouse α4β7
(clone DATK32), PE-conjugated anti-mouse CCR9 (clone
CW-1.2), PerCP-eFluor R© 710-conjugated anti-mouse IL-4
(clone 11B11), eFluor R© 450-conjugated anti-mouse IL-17A
(clone eBio17B7), PE-conjugated anti-mouse IL-17A (clone
eBio17B7), PE-conjugated anti-mouse anti-mouse T-bet
(Clone eBio4B10 (4B10, 4-B10), PE-conjugated anti-mouse
Gata-3 (Clone TWAJ), FITC-conjugated anti-mouse CD4
(clone GK1.5), eFluor R© 450-conjugated anti-mouse CD4
(clone RM4-5), APC-eFluor R© 780-conjugated anti-mouse
CD8 (clone 53-6.7), APC-conjugated anti-mouse FoxP3 (clone
FJK-16s), PerCP-eFluor R© 710-conjugated anti-mouse Vβ6
TCR (clone RR4-7), eFluor R© 450-conjugated anti-mouse Ly-6C
(clone HK1.4), PerCP-Cyanine5.5-conjugated anti-mouse CD19
[clone eBio1D3 (1D3)], PE-conjugated anti-mouse F4/80 (clone
BM8), FITC-conjugated anti-mouse CD11c (clone N418) were
purchased from eBioscience. PE/Cy7-conjugated anti-mouse
CD3 (clone 145-2C11), Brilliant Violet 785TM-conjugated anti-
mouse CD45 (clone 30-F11), Brilliant Violet 605TM-conjugated
anti-mouse CD11b (clone M1/70), Alexa Fluor R© 700-conjugated
anti-mouse Ly-6G (clone 1A8) were purchased from BioLegend.
The LIVE/DEADTM Fixable Aqua Dead Cell Stain (Cat L34957)
were purchased from ThermoFisher. Rabbit anti-mouse
Phospho-Akt (Ser473) (clone 193H12) was purchased from Cell
Signaling. Mouse neutralizing CCL25/TECKMAb (Clone 89818)
was purchased from R&D. Purified polyclonal goat anti-mouse
CCR9 Ab (NB100-708) was purchased from Novus.
For accuracy, in flow cytometric analysis of cells experiments,
gating settings based on staining with isotype-matched control
antibodies were made on a 1:1 mixture of cells from experimental
and control animals.
Generation of Bone Marrow-Derived DCs
Bone marrow (BM)-derived DCs were obtained from WT
C57BL/6 (H2-b) mice. Femurs from 7-to-10-week-old female
mice were removed and BM cells were flushed out with PBS
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using a 27-gauge needle (Fischer Scientific, Loughborough, UK).
Red blood cells were lysed from the cell suspension with lysis
buffer (Sigma). BM cells (5 × 106) were seeded per well in a six
well plate in RPMI 1640 medium supplemented with 10% FCS,
2mM glutamine, 50 IU/mL penicillin, 50µg/mL streptomycin,
50µM 2-ME, and 2% murine granulocyte-macrophage colony
stimulating factor (GM-CSF) obtained from the supernatant of
the GMCSF hybridoma (gift from Dr. Jian-Guo Chai, King’s
College, London, UK). Cells were cultured at 37◦C in the
presence of 5% CO2. On days 3 and 5, fresh culture medium
was added to the plates. DCs were matured overnight with
100 ng/ml lipopolysaccharide (LPS) and used between 7 and 10
days post-isolation.
Measurement of RALDH Activity in DCs
Cell aldehyde dehydrogenase (ALDH) activity was determined
by using the ALDEFLUOR staining kit (Stemcell Technologies,
Cambridge, UK) according to the manufacturer’s instructions.
In brief, DCs treated with or without 0.1µM citral were
resuspended at 106 cells/ml in ALDEFLUOR assay buffer
containing activated ALDEFLUOR substrate and incubated at
37◦C for 30min. ALDH inhibitor diethylaminobenzaldehyde
(DEAB) was used as negative control. ALDEFLUOR-reactive
cells were detected by flow cytometry in the FITC channel.
Intracellular Cytokine Staining
For stimulating cytokine production, T cells (2 × 106/mL)
were re-stimulated with irradiated unpulsed or Dby (Ab HY
epitope) peptide-pulsed B6 female T cell–depleted splenocytes (4
× 106/mL) in 24-well plates for 6 h in the presence of monensin
(GolgiStop; BD Biosciences Pharmingen). Cultured cells were
stained with antibodies for surface molecules. After washing,
cells were fixed, permeabilized with Cytofix/Cytoperm solution
(BD Biosciences Pharmingen), washed and resuspended in 1X
Perm/Wash solution (BD Biosciences Pharmingen) containing
antibodies for intracellular cytokines or isotype-matched control
antibodies. After a final wash, the cells were resuspended in
staining buffer for flow cytometric analysis.
Wide Field Deconvolution Fluorescence
Microscopy and Flow Cytometry
Tissue samples were either processed for flow cytometric analysis
(lymph nodes and spleen) or embedded in Optimal Cutting
Temperature compound (OCT, Agar Scientific Ltd, UK), snap-
frozen and stored until analysis.
Frozen tissue sections were laid onto Polylisine Microscope
slides (VWR International Lutterworth, Leicestershire, UK), left
to dry overnight, and then mounted in Vectorshield mounting
medium for fluorescence with DAPI (Vector Laboratories,
Peterborough), to visualize the nuclei. Slides were visualized
with a Coolview 12-cooled CCD camera (Photonic Science,
Newbury, UK) mounted over a Zeiss Axiovert S100 microscope
equipped with Metamorph software (Zeiss, Welwyn Garden
City, UK). A × 10 and NA 0.6 objectives and standard epi-
illuminating fluorescein and rhodamine fluorescence filter cubes
were used and 12-bit image data sets were generated. Tissue
infiltration was quantified by randomly selecting ten 10x-
magnified fields and assessing the number of fluorescent cells
in each field, as previously described (17). Quantification of T
cell infiltrates observed by wide field fluorescence microscopy
was performed using a purpose-designed software to run in
the LabView (V7.1, National Instruments) environment (17),
which allows identifying single fluorescent cells within the
tissue. To minimize the effect of arbitrary choice of field,
tissue infiltration was quantified by randomly selecting ten
10x-magnified fields from 3 to 6 tissue samples of each
tissue. The number of infiltrating cells obtained was then
averaged and assessed statistically. Infiltration is expressed as
the mean of fluorescent cells per ten 10x field in a given
experimental condition.
Flow cytometric analysis was performed using a LSR
FORTESSA (Becton Dickinson, Mountain View, CA) and FlowJo
version 7.6.5 software (Tree Star Inc, Ashland, OR, USA).
Measurement of AKT/PKB Phosphorylation
Naïve T cells and DCs were stimulated with 300 ng/ml CCL25
and harvested at the indicated time points, fixed with 2% PFA
for 15min at 37◦C, washed twice with PBS, permeabilized with
90% ice-cold methanol for 10min at −20◦C then washed twice
with PBS. Intracellular staining was carried out after initially
blocking permeabilized cells in RT FACS buffer (0.5% BSA/PBS
+ Na3VO4) for 30min and incubation with a dilution of
1:300 of Phospho-Akt (Ser473) rabbit anti-mouse antibody (Cell
Signaling Technology) for 30min at room temperature. Cells
were washed and stained with secondary APC-F(ab)2 fragment
donkey anti-rabbit IgG (H+L) (Jackson ImmunoResearch,
Suffolk, UK) at 1:300 for 30min at room temperature. Cells were
then analyzed using flow cytometry.
DCS STAINING WITH LABELED CCL25
DCs were incubated with Dylight 488-labeled (300 ng/ml,
Thermo Scientific, UK) CCL25 or albumin (control) for 40min,
followed by washing in PBS. One hundred and fifty microliters
of Dylight 488-CCL25 treated DCs were spread onto a slide
coated with poly-l-lysine (Sigma). Slides were incubated for
25min at 37◦C, followed staining with 1:50 hamster anti-
mouse CD11c antibody (clone N418, BioLegend). Samples were
fixed in 4% paraformaldehyde for 10min at 37◦C. Following
three washes in PBS, the sections were incubated with the
secondary antibody Alexa Fluor R© 555 goat anti-hamster IgG
(Life Technologies) for 30min at room temperature followed
by three washes. Sections were mounted on microscopy
slides with 4
′
,6-diamidino-2-phenylindole (DAPI) mounting
medium (Vectashield). Alternatively, cells were analyzed by
flow cytometry.
Helminth Infestation Model
Six to eight week old C57BL/6 mice were obtained from
Charles River UK Ltd (Margate Kent, UK). All experiments
were performed at least twice and the sizes of the experimental
groups were 3–5 mice per group per time point. Experimental
animals were infected with 150 embryonated Nippostrongylus
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brasiliensis eggs on day 0 by oral gavage. Maintenance and
recovery of the parasites were conducted as described previously
(18). To assess cytokine production, mesenteric lymph nodes
(MLN) and spleens were removed from uninfected and infected
animals and single cell preparations were resuspended in RPMI
1,640 supplemented with 10% heat-inactivated FCS, 2µM L-
glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin and
0.05µM 2-mercaptoethanol (all from Life technologies, Paisley,
UK). Cells were cultured at 37◦C and 5% CO2 in flat-bottomed
96-well plates (Nunc, Roskilde, Denmark) at a final concentration
of 5 × 106/ml in a final volume of 0.2 ml/well. Cells were
stimulated with N. brasiliensis ES antigen (25µg/ml) or plate-
bound anti-CD3 antibody (mAb145-2C11, 10µg/ml, ATCC).
Cell free supernatants were harvested after 48 h and stored at
−80◦C. Cytokine analyses were carried out using commercially
available sandwich ELISAs for IL-4, IFN-γ (Mabtech AB, Nacka,
Sweden), IL-13 and IL-10 (R&D systems, Abingdon, UK).
Pancreatic Ductal Adenocarcinoma Model
The KPC pancreatic ductal adenocarcinoma (PDAC) cell line
was derived from a KPC mouse generated from crossing the
LSL-Kras-G12D, LSL-p53-R172H, and Pdx-1-Cre mice (NCI,
Frederick, MD). Mice were immunized i.p. with 5 × 105 KPC
cells, which had previously undergone 5 rounds of freeze-
thawing in liquid nitrogen, mixed with 5 × 106 autologous
splenocytes in a volume of 100 µl PBS, with and without 0.06
mg/kg CCL25. For orthotopic implantation of KPC cells into
the pancreas of C57BL/6 mice, while the mice were anesthetized,
a small incision was made in the skin and peritoneal lining
and the pancreas externalized. Using a Hamilton R© syringe,
700 series, removable needle volume 25 µl, needle size 22 s
gauge (bevel tip) (#10100332, Fisher Scientific), ∼5 × 105
KPC cells in a volume of 5 µl PBS were injected into
the body of the pancreas. Mice were checked daily and the
experiment was terminated 28 days post orthotopic surgery.
Tumors were weighed after excision and processed for imaging or
flow cytometry.
Processing of Tumor Tissue
Pancreatic tumors were minced using a sterile scalpel blade and
single cell suspensions were generated using enzymatic digestion
(1 mg/ml Collagenase D, and 10µg/ml DNAse 1). Tumor debris
was removed using 70 micron filters (BD Falcon) before staining
for flow cytometry or RNA extraction.
Quantitative Real-Time Polymerase-Chain
Reaction (qRT-PCR)
Tissues were harvested and stored at −80◦C until processing.
Tissues were sliced and homogenized with stainless steel bead
using TissueLyser. RNA was purified using Qiagen RNAeasy
Kit according to the manufacturer’s instructions. Reverse
transcription was performed according to the manufacturer’s
instruction (Applied Biosystems). Gene expression analysis was
done using SYBR Green Supermix (Biroad) in CFX connect light
cycler (Biorad), according to the manufacturer’s instructions.
Primer sequences are below:
Gene Forward sequence Reverse sequence
GAPDH GGCAAATTCAACGGCACAGT AGATGGTGATGGGCTTCCC
HPRT GTAATGATCCAGTCAACGGG
GGAC
CCAGCAAGCTTGCAACCTT
AACCA
IFN-γ TCAAGTGGCATAGATGTGGAA
GAA
TGGCTCTGCAGGATTTTCATG
IL-5 GCCAGCGCTGAAGACTTC CTTGTCAACAGAGCTCGGTG
IL-17 TTTTCAGCAAGGAATGTGGA TTCATTGTGGAGGGC AGAC
TGF-β CCATCCATGACATGAACCGG TGGTATCCAGGGCTCTCC
CCL8 CAGTCACCTGCTGCTTTCAT ACAGCTTCCATGGGGCAC
CCL10 CCCTCTCCTTCCTCATTCTTACA AGTCTTGAAAGCCCATGTGAAA
IL1-β TGAGCTTTGTACAAGGAGAACC GGTGTGCCGTCTTTCATTACA
Statistical Analysis
Results are expressed as mean standard error of the mean (SEM)
or mean SD. The Student’s t-Test and ANOVA test were used.
All reported p-values are two-sided. A p value of <0.05 was
regarded as significant.
RESULTS
Activated CCR9+ CD4+ T Cells Acquire
α4β7 Integrin Expression in vitro in the
Presence of DC-Bound CCL25
Following activation in the draining lymph nodes, T cells localize
to non-lymphoid tissue by expressing appropriate homing
receptors. We therefore began our investigation by evaluating the
effect of exposure to CCL25 during activation on the expression
of the gut homing receptor α4β7 during the generation of
T cell memory by a series of in vitro experiments. In our
hands, the CCL25 receptor CCR9 is expressed in ∼70% of
CD8+ and 4–15% of CD4+ naïve T cells (CD44lowCD62Lbright,
Supplementary Figures 1A,B), in line with previous reports
(19). A series of preliminary experiments using antibody-
activated naïve T cells showed that the presence of CCL25
optimally upregulated α4β7 expression by WT, but not CCR9-
deficient naïve T cells. This effect was observed only when
CCL25 was delivered to the cultures bound to autologous
DCs rather than in soluble form and when T cells were
allowed to directly interact with the DCs in the cultures
(Supplementary Figures 1C,D). As DC differentiation in GM-
CSF enhances retinaldehyde dehydrogenase (RALDH) activity
and production of retinoic acid (20), which in turn induces
gut-homing receptors (21), to detect CCL25-specific effects DCs
were pre-treated with the RALDH inhibitor 3,7-dimethyl-2,6-
octadienal(Citral) (Supplementary Figures 1E,F).
To confirm these observations, CFSE-labeled ovalbumin
(OVA)-specific TCR-transgenic OT-II T cells were stimulated
by antigen-pulsed DCs pre-exposed to increasing concentration
of CCL25, which led a proportional increase of α4β7-
expressing T cells in the divided population (Figures 1A,B). The
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FIGURE 1 | CCR9 signals promote the acquisition of gut-homing receptors during in vitro T cell activation. (A–C) OT-II T cells were labeled with CFSE (4µM) and
stimulated with OVA323−339-pulsed mature C57/Bl6 bone-marrow (BM)-derived DCs pre-treated with increasing concentrations of CCL25 (pre-DC) or PBS alone. As
a control, T cells were activated in the presence of retinoic acid (RA) or pre-treated with CCL25 and subsequently exposed to untreated antigen-presenting DCs
(pre-T). After 3 days, expression of the integrin α4β7 by CFSE
low T cells was assessed by flow cytometry. The bar graph shows the mean data from three experiment
of identical design each performed in triplicate (±SEM). In panel (C), the stimulation index calculated for the different cultures is shown (N = 3). Asterisks over each
column bar represent comparison with control. Asterisks over lines represent comparisons between the columns included between the lines. (D) Representative
confocal microscopy image of non-permeabilized DCs incubated with green Dylight 488-labeled CCL25 (300 ng/ml) or albumin (control) and counter-stained with
Hamster-anti-mouse CD11c. Scale bar = 40µm. (E,F) Naïve T cells (E) or DCs (F) were exposed to CCL25 (300 ng/ml) for up to 15min and phosphorylation of Akt at
serine 473 was assessed by antibody staining and flow cytometry. Representative histograms of the experimental conditions indicated beside each profile are shown
in the left-hand panels. pAktSer473 expression by non-stimulated T cells or DCs (T0, NS), and by T cells and DCs stimulated for 5min with anti-CD3 (1µg/ml) or LPS
(100 ng/ml), respectively, are shown. The right-hand panels show the mean fluorescence intensity (MFI) indicative of Akt phosphorylation obtained in 3 experiment of
identical design each performed in triplicate (±SEM, *p < 0.05 vs. NS). (G,H) Purified naïve T cells were exposed to the NB100-708 anti-CCR9 antibody (5µg/ml)
cross-linked with 2.5µg/mL Donkey–anti-goat IgG for up to 15min and phosphorylation of Akt at serine 473 (pAktSer473 ) was assessed by flow cytometry.
(G) Representative histograms of T cells stained with the pAkt-specific antibody are shown in the left-hand panel. pAktSer473 expression after 5-min stimulation with
anti-CD3 is shown. The mean MFI values obtained at the indicated time points obtained in three experiments of identical design each performed in triplicates is shown
on the right-hand panel (±SD, *p < 0.05, **p < 0.01 vs. time 0, NS), which includes pAktSer473 expression by CCR9-competent T cells in the presence an
Isotype-matched antibody (IsC) (WT) and by ccr9−/− T cells (KO) incubated with the anti-CCR9 Ab. (H) In some T cells CCR9 was antibody-activated in the presence
of pertussis toxin (PTX, 0.1µg/ml). A histogram displaying pAktSer473 measured at 10min after stimulation is shown on the left hand side. The mean MFI values
obtained in three experiments of identical design each performed in triplicates are shown in the right-hand panel (±SD). *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.001.
presence of CCL25 however did not affect the rate of T cell
division (Figure 1C).
With the exception of a tolerogenic plasmacytoid subset, DCs
do not express CCR9 (22). However, confocal imaging of CCR9-
depleted bone marrow-derived DCs exposed to labeled CCL25
(or Albumin as a control) revealed that the chemokine was
bound to a large proportion of DCs (Figure 1D), indicating
that DC immobilize CCL25 independently of CCR9 expression.
Further experiments confirmed that binding of CCL25 to
DCs does not elicit Akt activation, while small but consistent
Akt phosphorylation (comparable to that induced by CD3
antibody-triggering) occurred in naïve T cells exposed to
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FIGURE 2 | CCL25 promotes differentiation of an antigen-specific, α4β
high
7 CD4
+ T cell population. TCR-transgenic, MY (A,B) or OT-II (C,D) naïve T cells
(107/mouse) were labeled with CFSE (4µM) and injected intravenously into WT and ccl25−/− syngeneic female recipients. Twenty-four hours later, recipient mice
received cognate peptide (100 µg Dby or 0.5 µg OVA-DEC peptide) plus ODN adjuvant (50 µg/mouse) orally. As a control, some mice received adjuvant only (ODN
alone). Five days after immunization, T cells were separately harvested from mesenteric LN (draining LN, dLN), Peyer’s Patches (PP), inguinal and axillary (non-draining
LNs, ndLN) and the spleen. T cells were identified by gating on the CD4+ Vβ6+ (MY) or Vβ2+ (OTII) lymphocyte populations. Expression of α4β7 (A,C) and CCR9
(B,D) by divided T cells was assessed by flow cytometry. In similar experiments depicted in panels (E,F), CD4+ T cells from Marilyn mice (MY 107/mouse) were
labeled with CFSE (4µM) and adoptively transferred into syngeneic female recipients, which received an intraperitoneal injection of CCL25-neutralizing antibody
(Anti-CCL25, 10 mg/kg) or Isotype Control antibody (IsC Ab). Twenty-four hours later, recipient mice received cognate Dby peptide (100 µg) plus ODN adjuvant (50
µg/mouse) orally. Five days after immunization, T cells were separately harvested from mesenteric LN (draining LN, dLN), Peyer’s Patches (PP), inguinal and axillary
(non-draining LNs, ndLN) and the spleen. T cells were identified by gating on the CD4+ Vβ6+ (MY) lymphocyte populations. Expression of α4β7 (E) and CCR9 (F) by
divided T cells was assessed by flow cytometry. In all panels, the mean number of divided α4β
+
7 and CCR9
+ T cells from three independent experiments of identical
design is shown below a set of representative dot plots (±SD). Staining with an isotype-matched control antibody and proliferation and differentiation in draining lymph
nodes of mice injected with adjuvant alone are shown on the right-hand side of each set of dot plots. To avoid the reciprocal effect of the presence of other responder
T cell populations, results are presented as absolute numbers. *p < 0.05, **p < 0.01.
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the chemokine (Figures 1E,F). The ability of CCR9 to elicit
signals in naïve T cells was confirmed by the induction of
Akt phosphorylation by a stimulatory anti-CCR9 antibody
(Figure 1G), which was prevented by exposure of the T cells to
pertussis toxin (PTX, Figure 1H).
CCL25 Promotes the Differentiation of a
Population of α4β
bright
7 CD4
+ T Cells in vivo
We next sought to establish the contribution of CCL25 to the
differentiation of CD4+ α4β
bright
7 T cells in physiologic conditions
during oral immunization.
First, we analyzed the localization of this chemokine in healthy
murine gut parenchyma and GALT. Endogenous CCL25 was
present in the gut lamina propria (LP) and Peyer’s patches
(PP) where it co-localized with CD11c+ cells, but not in
mesenteric and other LNs (Supplementary Figure 2A) in steady
state conditions. CCL25 was found on the vessels in the LP, but
not in GALT (Supplementary Figure 2B). Following induction
of inflammation, CCL25 was retrieved on CD11c+ cells also
in the mesenteric LNs (Supplementary Figure 2C), but not
on high endothelial venules (HEV, Supplementary Figure 2D),
suggesting that gut-produced CCL25 is transported to the
draining LNs via CD11c+ cells (likely migratory tissue-derived
DCs)—as unbound CCL25 directly transported to the LN would
diffuse and bind to HEV.
Next, purified naïve TCR-transgenic Marilyn (MY, male
antigen HY-specific H2-Ab-restricted, Figures 2A,B) or OT-II
(Ovalbumin-specific, H2-Ab-restricted, Figures 2C,D) T cells
were labeled with CFSE, and adoptively transferred into female
ccl25−/− and WT recipients (H2-b haplotype), which were
subsequently immunized orally with cognate peptide in 50 µg
of CpG ODN adjuvant. Five days later T cells were isolated
from draining mesenteric lymph nodes (MLN, dLN), Peyer’s
patches (PP), spleen, and non-draining LNs (ndLN, inguinal
and axillary). Expression of α4β7 and CCR9 by T cells that
underwent division was monitored by flow cytometry. As shown
in Figure 2, discrete populations of α4β
high
7 (Figures 2A,C) and
CCR9+ (Figures 2B,D) T cells differentiated within dividing
TCR-transgenic T cells in dLN following oral immunization.
These populations were significantly reduced in ccl25−/−
recipients. Interestingly, while CCR9 upregulation occurred
in most proliferating T cells, only a small fraction of α4β7-
expressing T cells was consistently detected at the 4–5th round
of division. Administration of adjuvant alone did not lead to cell
division or upregulation α4β7. All α4β7-expressing T cells were
also CCR9+ (Supplementary Figure 2E).
In parallel experiments, treatment with a neutralizing CCL25
antibody significantly reduced the development of α4β
+
7 CCR9
+
T cells in dividing MY T lymphocytes transferred into syngeneic
C57BL/6 female (23) during priming (Figures 2E,F). The
role of CCR9 signals in the development of this T cell
population was further confirmed in similar experiments in
which lack of CCR9 expression by adoptively transferred T
cells resulted in a significantly reduced number of divided
T cells expressing α4β
+
7 in the GALT in response to allo-
immunization (Supplementary Figure 2F).
CCR9 Signals Promote the Development of
a Th1-Like Phenotype by Inducing
Expression of the Transcription Factor
T-Bet
The experiments described above also revealed that IFN-
γ production by α4β
+
7 MY and OT-II primed T cells
was impaired in CCL25-deficient mice immunized orally
(Figures 3A–D). Differentiation of IL-4- or IL-17-producing
T cells in the proliferating populations appeared unaffected
(Supplementary Figures 3A,B).
To further explore this observation, cultures were set up
to assess the effect of CCR9 signals on T-bet expression.
A stimulatory anti-CCR9 antibody (Figures 1G,H) capable of
mimicking the effects of CCL25 on CD4+ T cell differentiation
in vivo (Supplementary Figures 3C,D) was used in these
experiments, as induction of T cell differentiation by CCL25
requires the presence of DCs, which might provide additional
T-bet-inducing signals. T cells were stimulated with plate-
bound anti-CD3 in the presence of the CCR9-stimulating or
isotype-matched control antibody. As a positive control for Th1
differentiation, T cells were activated in the presence of IL-
12 and anti-IL-4 mAb. Antibody triggering of CCR9 during
activation with anti-CD3 led to a significant increase of IFN-
γ-producing α4β
+
7 T cells (Figure 3E). Importantly, enhanced
production of IFN-γ was accompanied by expression of the
Th1-associated transcription factor T-bet selectively in α4β7-
expressing T cells (Figure 3F). This, in turn, was inhibited by
treatment with pertussis toxin (PTX), confirming that CCR9
signals directly and selectively promote the differentiation
of Th1 properties in α4β
+
7 T cells. Control experiments
were conducted with CCR9-deficient T cells, which failed to
upregulate T-bet in response to the CCR9-stimulating antibody
(Figure 3G). Additionally, antibody-activation of CCR9 led to
STAT1 activation (Figure 3H), a response associated with the
development of a Th1 phenotype (24).
Optimal expression of α4β7 by CD4
+ T cells has been found
to be regulated by basic leucine zipper transcription factor,
ATF-like (BATF), an AP-1 protein family factor (25). Antibody-
activation of CCR9 concomitant to TcR and CD28 engagement
induced BATF transcription (Figure 3I) and protein expression
by CD4+ (Figure 3J) T cells, thus highlighting an additional
transcriptional mechanism by which CCR9 signals affect T
cell differentiation.
Ectopic Administration of CCL25 Induces
the Differentiation of α4β
+
7CCR9
+ Th1 Cells
CCL25 is not produced in the skin (3, 26) and priming in skin-
draining LNs prevents the development of α4β
+
7 T cells (27)
due to inhibition of RALDH activity by PGE2 (28). To rule out
that CCL25-mediated accumulation of α4β
+
7 CCR9
+-expressing
naïve T cells in the GALT prior to priming might underlie the
expansion of α4β
+
7 T cells, the chemokine was delivered in the
subcutaneous tissue together with cognate antigen. To reflect
physiologic conditions, the dose of CCL25 was estimated based
on the concentration of CCL25 measured in the murine non-
inflamed ileum in vivo (300 pg/ml) (29), and corrected by the
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FIGURE 3 | CCR9 signals induce α4β
+
7 Th1-like cells. MY (A,B) or OT-II (C,D) naïve T cells (10
7/mouse) were labeled with CFSE (4µM) and injected intravenously
into WT and ccl25−/− syngeneic female recipients. Recipient mice received cognate peptide (100 µg Dby or 0.5 µg OVA-DEC peptide) plus ODN adjuvant (50 µg)
orally 24 h later. Five days later, T cells were separately harvested from mesenteric LN (draining LN, dLN), inguinal and axillary (non-draining LNs, ndLN) and the
spleen. Production of IFN-γ by divided MY (A) and OT-II (C) T cells was assessed by intracellular staining and flow cytometry. T cells were identified by gating on the
CD4+ Vβ6+ (MY) or Vα2+ (OTII) populations. Panels (C) and (D) show the production of IFN-γ by α4β
+
7 divided MY an OTII T cells, respectively. The mean number of
T cells from three independent experiments of identical design is shown below each set of representative dot plots (±SD, n = 3, N = 2). (E,F) Naive T cells
(Continued)
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FIGURE 3 | were activated either with plastic bound anti-CD3 in culture medium, or under Th1-skewing culture conditions or in the presence of an activating CCR9
antibody (7µg/ml). In some experiments, T cells were activated in the presence of the anti-CCR9 antibody in the presence of pertussis toxin (PTX, 0.1µg/ml).
Representative dot-plots of IFN-γ+α4β
+
7 and T-bet
+α4β
+
7 T cells (gated on CD3
+CD4+ populations) 5 days after activation and the mean number of T cells from
three independent experiments of similar design is shown in panels (E,F), respectively (±SD). Of note, Th1-skewing culture led to T-bet expression mainly in α4β
−
7 T
cells (F). (G) WT and ccr9−/− naive T cells were activated either with plastic bound anti-CD3 under Th1-skewing culture conditions or in the presence of an activating
CCR9 antibody (7µg/ml). Five days later, expression of T-bet was assessed by flow cytometry. A representative histogram and the mean T-bet MFI from three
independent experiments of similar design are shown (±SD). (H) Naive T cells were activated either with plastic bound anti-CD3 and antiCD28 under Th1-skewing
culture conditions or in the presence of an activating CCR9 antibody (7µg/ml) or isotype-matched antibody control. Three days later, expression of phosphorylated
(p)STAT1 (Ser727) was assessed by flow cytometry. Representative histogram and the mean pSTAT1 MFI from three independent experiments of similar design are
shown (±SD). (I,J) Naïve WT T cells were stimulated with plate-bound anti-CD3 and CD28 antibodies in the presence of either 7µg/mL anti-CCR9 or isotype control
antibody cross-linked with 2.5µg/mL Donkey–anti-goat IgG overnight. T cells were harvested and expression of BAFT mRNA (I) protein (J) by CD4+ T cells was
assessed by real-time PCR and intracellular staining, respectively. Staining with an isotype-matched control antibody and proliferation and differentiation in
draining lymph nodes of mice injected with adjuvant alone are shown on the right-hand side of each set of dot plots. Bar graph show the mean values obtained in
three experiments of identical design each performed in triplicates (±SD). *p < 0.05, **p < 0.01, ***p < 0.001, ****p <0.0001.
concentration of subcutaneously administered drugs measured
in the draining LNs (i.e., 1/1,000 of the injected dose) (30).
Dylight 488-labeled CCL25 injected s.c. was detected on
CD11c+ cells, but not on CD31+ vascular structures of draining
LNs (Figure 4A). In addition, administration of CCL25 in the
absence of antigen did not increase the localization of CCR9+
α4β
+
7 naïve T cells in the draining LNs compared to injection of
saline solution (Supplementary Figures 4A,B).
As shown in Figure 4B, following s.c. immunization of Rag2-
deficientMarilynmice with male-derived splenocytes co-injected
with CCL25, a significantly larger population of α4β
+
7 CD4
+ MY
T cells became detectable in both draining and non-draining
LN, PP and the spleen consistent with the ability of recirculating
T cells primed in the skin to rapidly migrate to both local
and distal lymphoid tissue (31). CCL25 injection alone did not
induce proliferation (not shown). Cytokine analysis revealed
an increase of IFN-γ -producing T cells (Figure 4C), which—
unexpectedly—was accompanied by a significant decrease of
IL-17-producing T cells (Figure 4D). Production of IL-4 was
unchanged (Supplementary Figure 4C).
We further explored the differentiation of cytokine-producing
CD4+ T cells activated in skin-draining LNs in the presence
of CCL25 by assessing the expression of α4β7, CCR9, IFN-γ,
and IL-17 by- and the recirculation of- adoptively transferred
OTII T cells. α4β
+
7 CCR9
+ OTII T cells differentiated in skin-
draining LNs by 3 days after activation (Figures 4E–G and
Supplementary Figures 4D,E), and subsequently exited this site
and selectively localized to the MLN by day 7 (Figures 4H–J
and Supplementary Figures 4D,E), where they had also began
to produce IFN-γ (Figure 4I and Supplementary Figure 4F).
In this instance, we did not observe increase of gut-homing
T cells induced in the presence of CCL25 in all lymphoid
sites, possibly reflecting the smaller size of the adoptively
transferred TCR-transgenic T cell population compared to that
available during immunization of mice with a wholly transgenic
TCR repertoire.
In contrast, IL-17-producing T cells did not change in
the dividing population containing IFN-γ producing T cells
(Figures 4G,J). However, we noticed that the number of IL-17-
producing OTII T cells (Figure 5A) was significantly decreased
in the CFSElow T cells 5 days after immunization, suggesting the
possibility that CCL25 affects the differentiation of IL-17+ OT-II
T cells from naïve precursors distinct from those generating
α4β
+
7 IFN-γ-producing T cells. Furthermore, IL-17
+ OT-II T
cells were mainly detected in skin dLN and did not localize to the
GALT. Analysis of OT-II T cells retrieved in the dLN following
oral immunization of WT and CCL25-deficient mice confirmed
that IL-17-producing T cells preferentially expand in the gut in
ccl25−/− animals (Figure 5B).
CCL25-Induced Memory T Cells Localize
to the Gut Wall and Peyer’s Patches and do
Not Recirculate Upon Remote Antigen
Challenge
Differentiation α4β
+
7 T cells induced by CCR9 signals in vivo
consistently occurred in a small population of activated T cells
(Figure 2) suggesting that only a fraction of TCR-transgenic
CCR9+ T cells undergoes such differentiation pathway. The
generation of these T cells by s.c. immunization in the presence
of CCL25 provided the opportunity to further characterize
this population without the need to discriminate them from
other α4β
+
7 CCR9
+ T lymphocytes already present in the
GALT microenvironment.
First, we sought to confirm that T cells primed in the presence
of CCL25 in the subcutaneous dLN develop topographic memory
for the GI tract and associated lymphoid tissue and to define their
distribution within this organ. CD44high T cells were isolated
from dLNs of Marilyn-rag2−/− mice immunized subcutaneously
(s.c.) either in the presence or absence of CCL25, then labeled and
adoptively transferred into syngeneic C57BL/6 male recipients. T
cell localization in a number of sites was analyzed 24 h later by
wide field fluorescence microscopy. As shown in Figures 6A–C,
adoptively transferred T cells activated in the presence of CCL25
preferentially localized to MLNs and PP compared to those
primed in the presence of saline solution. Strikingly, only T cells
activated in the presence of CCL25 gained access to the gut wall
(Figure 6A and Supplementary Figure 5), where they localized
in the LP as well as in the epithelial layer.
Second, we assessed the ability of these T cells to recirculate
by delivering a remote antigen challenge. Primed CD44high
fluorescent TCR-transgenic T cells were isolated from the
spleen and dLN of DsRed-expressing Marilyn-Rag2−/− mice
immunized s.c. with male splenocytes and CCL25 a week earlier.
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FIGURE 4 | Subcutaneous co-delivery of antigen and CCL25 induces the development of α4β
high
7 Th1 T cells. (A) Dylight 488-labeled CCL25 (0.06 mg/kg) was
subcutaneously injected into mice. Two hours later, the dLNs were harvested. Tissue sections from dLN were stained with hamster anti-mouse CD11c antibody (clone
N418, BioLegend), or rat anti-mouse CD31 Antibody (MEC13.3, BioLegend) overnight at 4◦C. Following three washes in PBS, the sections were incubated with the
secondary antibody Alexa Fluor® 546 goat anti-hamster IgG or Alexa Fluor® 555 goat anti-rat IgG (Life Technologies) for 30min at room temperature followed by
three washes. Sections were mounted on microscopy slides with 4
′
,6-diamidino-2-phenylindole (DAPI) mounting medium (Vectashield). Images taken by wide field
fluorescence microscopy are shown. Scale bar, 20µM. (B–D) Female Marilyn-rag2−/− mice were immunized by subcutaneous administration of 5 × 106
male-derived splenocytes in saline solution or the presence of 0.06 mg/kg CCL25. One week later T cells were separately harvested from axillary (draining LNs, dLN),
PP, mesenteric LN (non-draining LN, ndLN), and spleen. Marilyn (MY) T cells were identified by gating on the CD4+Vβ6+ T cell population. The number of α4β
high
7
(B), IFN-γ- (C) or IL-17-expressing (D) T cells was measured by flow cytometry. The mean number of T cells from two independent experiments of identical design is
shown below each set of dot-plots (±SD, n = 3). (E–J) OT-II naïve T cells from (107/mouse) were labeled with CFSE (4µM) and injected intravenously into syngeneic
recipients, which were immunized 3 h later by s.c. administration of 0.5 µg OVA-DEC plus 50 µg poly IC adjuvant (InvivoGen) re-suspended in saline solution or in the
presence of CCL25 (0.06 mg/kg). T cells were separately harvested from draining LN (axillary, dLN), mesenteric LNs (mLNs), Peyer’s Patches (PPs) and spleen 3
(Continued)
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FIGURE 4 | (E–G) and 5 days (H–J) later. Expression of α4β7 (E,H) and IFN-γ (F,I) or IL-17 (G,J) by CFSE
low T cells was assessed by flow cytometry by gating on
CD4+Vα2+ T cells (OTII TCR). Staining with an isotype-matched control antibody in draining lymph nodes of mice injected with adjuvant alone are shown on top of
each set of dot plots. The mean values obtained in at least 3 experiments of identical design are shown below each set of representative dot plots (±SD). *p < 0.05.
FIGURE 5 | CCL25-induced TRM cells reduce differentiation of IL-17-producing T cells. OT-II naive T cells were labeled with CFSE (4µM) and injected intravenously
into syngeneic recipients (107/mouse), which were immunized 3 h later by s.c. (A) or oral (B) administration of 0.5 µg OVA-DEC plus 50 µg poly IC adjuvant
(InvivoGen) re-suspended in saline solution or in the presence of CCL25 (0.06 mg/kg). T cells were separately harvested from draining LN (axillary, dLN), mesenteric
LNs (mLNs), Peyer’s Patches (PPs) and spleen 5 days later. Expression of IL-17 by T cells was assessed by flow cytometry by gating on CD4+Vα2+ (OTII TCR)
CFSElow T cells. For clarity, the plots displaying CFSE dilution on divided T cells are shown on the left-hand-side of each panel, in which the red squares indicate the
gate used for detection of IL-17+ T cells. The mean values obtained in at least three experiments of identical design are shown below each set of representative dot
plots (±SD, n = 3). *p < 0.05.
Following isolation from LN and spleen, T cells were adoptively
transferred into naïve female C57BL/6 recipients. A week later,
mice were challenged with antigen (Dby peptide) either orally
(Figure 6B) or s.c. (Figure 6C) without co-injection of CCL25.
The presence of fluorescent MY T cells in the draining and
non-draining LNs and PPs was assessed for up to 4 days later.
Following oral re-challenge the majority of DsRed MY T cells
converged to the MLN and PP (Figure 6B), irrespectively of
expression of α4β7 and/or CCR9. Similarly, antigenic challenge
s.c. led to T cell localization to the draining axillary LNs
(Figure 6C), suggesting that the majority of T cells primed in
the presence of CCL25 recirculate and migrate to remote sites
of antigen challenge. However, the α4β
+
7 CCR9
+ T cell subset
induced by s.c. immunization with CCL25 remained localized
to the mLN and PP upon remote (s.c.) antigen administration
(Figure 6D). Even co-delivery of the chemokine CCL25 during
antigen re-challenge s.c. did not elicit migration of these T cells
to the skin-draining LNs (Figure 6E), suggesting that CCL25-
induced α4β
+
7 CCR9
+ T cells do not recirculate once localized in
the gut wall and associated lymphoid tissue.
We therefore analyzed the expression of receptors associated
with lymphoid and non-lymphoid tissue retention signals by
α4β
+
7 CCR9
+ MY T cells, which had divided (i.e., CFSE-low)
upon s.c. immunization in the presence of CCL25 a week earlier.
As a control, the phenotype of MY T cells divided following
immunization in saline solution was analyzed. As shown in
Figure 6F, a larger proportion of α4β
+
7 CCR9
+ MY T cells
displayed CD62L compared to α4β
−
7 CCR9
− divided MY T cells.
Both T cell populations expressed the S1PR1 (Figure 6G), a
key receptors necessary for T cell egress from lymph nodes
(32). However, only α4β
+
7 CCR9
+ T cells expressed the S1PR1-
blocking molecule CD69 (Figure 6H) (33), which is required
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FIGURE 6 | CCL25-induced α4β
+
7 CD4
+ T cells localize to the GI tract and do not recirculate. T cells isolated from dLN of Marilyn-rag2−/− mice immunized s.c. with
male splenocytes either in the presence or absence (saline) of the chemokine CCL25 (0.06 mg/kg) were labeled with the red-fluorescence cell-linker PKH26 (2µM)
and injected i.v. (107/mouse) into syngeneic C57BL/6 male recipients. Localization of labeled T cells in the indicated tissues was analyzed 24 h later by wide field
fluorescence microscopy. Representative images and the mean number of labeled cells detected in at least three samples from each recipient in three independent
experiments (n = 3) are shown in (A). Scale bar: 300µm. CD44hi DsRED-expressing Marilyn T cells were isolated by cell sorting from the dLN (axillary) and spleen of
mice immunized s.c. 7 days earlier in the presence of CCL25. (B,C) T cells were subsequently transferred into naïve female C57BL/6 recipients, which received an
antigen challenge in saline solution orally (B) or s.c. (C) a week later. The presence of DsRED Marilyn (MY) T cells in the dLNs, ndLN and PPs was assessed 4 days
after antigenic challenge. MY T cells were further identified by the expression of Vβ6. The mean number of T cells from at least three recipients (±SD) is shown on the
right-hand-side of representative dot-plots (*p < 0.05). (D,E) Recipients of T cells from mice primed s.c. in the presence of CCL25 were also antigen-re challenged
s.c. in the absence or presence of CCL25. To discriminate the α4β
+
7 and CCR9
+ cells within the MY CD4+ T cell population gating was set on DsRED and CD4.
(Continued)
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FIGURE 6 | DsRED Marilyn (MY) T cells in the dLNs, ndLN, and PPs were analyzed 4 days after antigenic challenge. The mean number of T cells from at least three
recipients (±SD) is shown on the right-hand-side of representative dot-plots (*p < 0.05, **p < 0.01). (F–I) CD4+ T cells from Marilyn-rag2−/− mice (107/mouse) were
labeled with CFSE (4µM) and injected intravenously into female syngeneic recipients. Recipient mice were immunized 24 h later by s.c. administration of 5 × 106
male-derived splenocytes re-suspended in saline solution or in the presence of CCL25 (0.06 mg/kg). One week later, T cells were separately harvested from draining
LN (axillary, dLN), mesenteric LNs (mLNs) and Peyer’s Patches (PPs) and spleen. Expression of the indicated molecules was assessed by flow cytometry. Comparison
are made on Marilyn T cells identified by gating on the total divided CD4+Vβ6+CFSElow T cell population from mice immunized in the presence of saline, and on the
CD4+Vβ6+CFSElowα4β
high
7 T cell population from mice immunized in the presence of CCL25. CD4
+Vβ6+CFSElowα4β
high
7 T cells were retrieved in negligible
numbers from mice immunized in the presence of saline, making it unfeasible to analyze this population. In panel (F), representative dot plots are sided by graphs
representing the mean % of T cells detected in at least three animals, In panels (G–I), representative histograms of CCL25-induced or control T cells are shown. The
blue histograms depict staining with an isotype-matched control antibody (IsC). In each panel, the column graphs display the mean delta MFI (experimental MFI—IsC
MFI) detected in T cells from three animals (±SD, *p < 0.05, **p < 0.01, ***p < 0.001) (N = 2).
for the retention of T cells in the PPs (34), and αEβ7 integrin
(Figure 6I), which mediates adhesion of T cells to the epithelium
(35) and is characteristically expressed by IELs (1). Thus, CCL25-
induced α4β
+
7 CCR9
+ T cells display phenotypic features similar
to those of TRM cells.
CCL25-Induced Th1 Cells Regulate the
Tissue Immune Environment
We finally tested the hypothesis that the ability of CCL25-
induced α4β
+
7 CCR9
+ mucosal T cells to influence cytokine
production might enable them to define the tissue
microenvironment. As strong Th1 responses are bound to
occur during most bacterial GI infections rendering it difficult
to discriminate the role of this small population from overall
immune activation we first assessed the impact of CCL25-
deficiency in a model ofN. brasiliensis infection in mice, in which
resistance is dependent on CD4+ T cells of the Th2 type (31).
WT and CCL25-deficient mice were infected with
embryonated N. brasiliensis eggs, and worm burdens, fecal
egg count (FEC) and cytokine responses ex vivo were analyzed
at specific time points post infection. As it is shown in
Figures 7A–C, lack of CCL25 resulted in a relatively small but
significant delay in worm clearance, which was associated with
reduced IFN-γ and increased IL-17 and IL-5 production in the
local lymph nodes, whilst and IL-4 and IL-13 secretion was
unaffected. Intestinal mRNA expression analysis confirmed that
lack of CCL25 resulted in significantly decreased IFN-γ and
increased IL-17 mRNA expression in the gut (Figure 7D). No
change in IL-33 mRNA expression was observed, suggesting that
CCL25 deficiency unlikely affects epithelial cells.
Having established that the CCL25/CCR9 axis influences
physiological immunity in the intestine by cytokines, we
investigated whether induction of the Th1 α4β
+
7 population
could also modulate tissue immune cell infiltrates, as it
has been shown for TRM (9, 36). We chose to assess the
effect of co-delivering immunogen and CCL25 on anti-tumor
immune responses in a model of orthotopic PDAC model.
In the PDAC microenvironment, the prevalent immune cells
tending to promote tumor progression via immunosuppression
include T regulatory cells (Treg), Myeloid Derived Suppressor
Cells and Type 2 Tumor Associated Macrophages, while
dampening immune effector cells (mainly CD8+ and CD4+
T cells, Dendritic Cells (DCs) and Natural Killer Cells) (37).
We confirmed previous reports in humans that Mucosal
Addressin Cell AdhesionMolecule (MAdCAM)-1, which enables
access by α4β
+
7 T cells is expressed at high levels by
the vascular endothelium of PDAC (Figure 7E) but not of
adjacent tissue (38). Mice were immunized intraperitoneally
with tumor cell lysates in the presence or absence of CCL25 a
week before receiving intrapancreatic PDAC cell injection,
having previously confirmed that also this immunization
route in the presence of CCL25 induces the differentiation
of α4β
+
7 Marilyn T cells (Supplementary Figure 6). Mice
were sacrificed 28 days after tumor implantation, and the
tumor was weighted and processed for analysis. As shown
in Figure 7F, tumor growth was significantly reduced in
mice previously immunized in the presence of CCL25. A
detailed analysis of immune cell infiltrates showed a significant
increase of CD3-expressing cells (Figure 7G) without increase
of CD4+ or CD8+ populations (Supplementary Figures 7A,B).
In addition, a significantly larger number of T cells expressed
higher levels of PD-1 (Figures 7H,I), without increase of
CD4+ FoxP3+ T cells (Supplementary Figure 7C), indicating
immune activation. These tumors contained higher numbers
of inflammatory monocytes, macrophages and dendritic cells,
while B-cell and granulocyte numbers remained unchanged
(Supplementary Figures 7D–H). We did not detect changes in
the production (Supplementary Figures 7I,J) or transcription
of IL-17 and IFNγ (Supplementary Figure 7K), but detected a
significant decrease in TGFβ mRNA (Figure 7J).
As the PDAC cell line was found to spontaneously produce
CCL25 (Supplementary Figure 8A), and delivery of chemokine
to tumor-bearing, non-immunized mice was not effective due
to the extremely fast tumor growth, we further sought to
rule out the role of chemotactic activity by the tumor itself
and to assess its expansion in recipient unable to produce
CCL25. To this aim, tumor growth and immune-environment
characteristics were compared in WT and ccl25−/− immunized
recipients (without CCL25). As shown in Figure 7K tumor
growth was increased in CCL25-deficient recipients, and a
detailed analysis of immune cell infiltrates revealed a significantly
increased number of FoxP3 CD4+ T cells (Figure 7L), which was
accompanied by a significantly larger number of PDI-expressing
cells (Figure 7M) but without upregulation of this molecule on
a per cell basis (Figure 7N). Analysis of cell infiltrates revealed
an overall decrease in inflammatory cells and cytokines, with
no changes in Tgfb transcripts (Supplementary Figures 8B–N).
Collectively, these data show that CCL25 physiologically
promotes anti-tumor responses in the GI system by modifying
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FIGURE 7 | CCL-induced TRM cells affect T cell responses by modifying the immune environment. Intestinal wormburden and fecal expulsion of helminth by WT mice
and ccl25−/− infected with N. brasiliensis are shown in panels (A) and (B), respectively. In panel (C), production of the indicated cytokine from in vitro worm
antigen-stimulated mesenteric lymph node cultures. Expression of IFN-γ, IL-17, IL-10, IL-4, IL-13, and IL-33 mRNA in intestinal tissue from infected mice is shown in
panel (D). n = 5 in each group. Data are representative of two independent experiments (mean ± SEM, *p < 0.05). Expression of MAdCAM-1 molecules by vascular
endothelium in orthotopic PDAC is shown in panel (E). Mice were immunized with tumor cell lysates and syngeneic splenocyte with and without CCL25 a week before
receiving intrapancreatic tumor cell implants. Panel F, weight of tumors excised 28 days after implantation. Tumor immune cell infiltrates were subsequently analyzed
for the presence of CD3+ T cells (G) CD4+PD1+ T cells (H) and intensity of PF1 expression on these cells (I). The presence of Tgfβ mRNA was assessed by RT-PCR
(J). In parallel experiment WT and CCL25-deficient mice were immunized with tumor cells and syngeneic splenocyte lysates a week before receiving intrapancreatic
tumor cell implants. Panel (K), weight of tumors excised 28 days after implantation. Tumor immune cell infiltrates were subsequently analyzed for the presence of
CD4+FoxP3+ cells (L), CD4+PD1+ cells (M) and intensity of PF1 expression on these cells (N) n > 5 N = 4 *p < 0.05; **p < 0.01.
the immune microenvironment rather than by means of its
chemotactic activity.
DISCUSSION
This study describes a Th1 population, which develops as a result
of CCR9 signals delivered during priming, maintains expression
of α4β7 integrin, display phenotypic features similar to those of
TRM and localizes in the gut wall and GALT.
The concept that mucosal immune surveillance is solely
carried out by circulating α4β
high
7 memory T cells, has been
challenged by the observation that α4β7 integrin is lost by
the majority of recirculating memory T cells—including those
activated in the GALT—despite the maintenance of protective
immunity (39). However, while expression of α4β7 integrin
is not required for efficient T cell entry in the intestine and
pathogen clearance during primary infections, α4β7 integrin
is crucial for protection against subsequent infection. The
development of mucosal α4β7 TRM cells has been recently
confirmed to be necessary for optimal pathogen clearance
in a model of genital Chlamydia trachomatis infection (40).
Together with this evidence, our own findings indicate that
following priming α4β7 persists only in a small, discrete
population of Th1 cells, suggesting that α4β7 expression is
essential for the localization and retention of mucosal T cells.
Although parabiosis experiments will be required to formally
define the CCL25-induced Th1 cells that we describe here as
TRM cells, their phenotypical feature, mucosal and epithelial
localization, lack of recirculation upon remote antigen challenge
and long-term effect on the immune microenvironment
in tumors suggest that these cells are functionally more
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similar to TRM cells than those activated in the absence
of CCL25.
Similarly to IELs, CCL25-induced mucosal Th1 cells express
αEβ7, which might facilitate their adhesion to the gut epithelium
(35), as well as other typical markers of TRM cells. Importantly,
this subset specializes in the production of IFN-γ. TRM cells
have been shown to exert their protective role by producing
cytokines including IFN-γ (41, 42), which serve to enhance
expression of adhesion molecules by the vascular endothelium
and subsequently promote recruitment and activation of other
immune cells (43). In line with these reports, we show that a
key function of CCL25-induced Th1 TRM cells is to modulate
the immune microenvironment and ultimately the immune
response in an indirect manner, by regulating the recruitment
and activation of other immune cells (as we have observed in
the PDAC model), or their function (such as in the parasite
infestation model). This concept is best illustrated by the recent
report that antigenic re-challenge of TRM cells in the skin can
induce a non-antigen-specific state of alert, with increased tissue-
wide expression of a substantial number of innate immune
response genes, including interferon-induced transmembrane
protein-3 (12). These findings also provide an explanation for the
paradox that, despite displaying only minor quantitative defects
in gut IELs, genetic ablation of the CCR9/CCL25 axis in mice
leads to exacerbation of intestinal T cell responses, accompanied
by increased IL-17 production (15, 44, 45). Consistently with
these observations, we show that the development of CCL25-
induced mucosal Th1 cells correlates with a decrease of IL-17-
producing T cells from distinct naïve T cell precursors both
in vitro and in vivo. The molecular mechanism of this effect is at
present unclear, but it is likely to be related to the impact of CCL-
25 inducedmucosal Th1 cells on the immunemicroenvironment,
as suggested from our studies in the helminth infestation and
PDAC models.
The transcriptional regulation of TRM cell has recently
received much attention (9), especially in view of the
identification of phenotypically and functionally distinct
Th17- and Th1-like TRM cells in the skin (46), however little is
known about the stimuli that regulate their differentiation. Our
observations indicate that signals initiated by the CCL25/CCR9
axis induce mucosal Th1 cells. Specifically, CCR9 signals favor
the induction of a transcriptional program which includes T-bet
and BAFT expression. With respect to T-bet expression, CCR9
triggering might aid optimal positioning of naïve CCR9+ T cells
during priming as it has been shown for CXCR3 (47) and/or
stabilize cognate interactions with antigen-presenting DCs, thus
strengthening TCR signals and leading to Th1 differentiation
(48). Alternatively, or in addition, CCR9 signals might directly
influence T-bet expression by converging signals on the Jak-
STAT pathway (49). CCL25 might also enhance Th1 response
in an indirect manner, by enhancing their survival via Akt
activation. Further investigations are required to fully define
this mechanism.
Our observations further indicate that the CCR9-induced
transcriptional program leading to the differentiation of mucosal
Th1 cells is initiated during activation in the lymph nodes
and prior to their localization to the gut wall and GALT.
The failure by CCL25 to induce α4β7 TRM T cells in CCR9-
deficient T cells (unlike RA) and the detection of this small
cohort of T cells in a discrete population of divided T cells
could be explained by the existence of a pre-committed CD4+
CCR9+ α4β
+
7 precursor naïve T cell subset. Alternatively,
or in addition, specialized differentiation—in this case α4β7
expression and IFN-γ production—might occur in a cohort
of activated T cells upon very stringent conditions, such
as the strength of TCR signals (50) in conjunction with
CCR9 signals. In this instance, specialized differentiation is
reflected by a specific number of cell divisions undergone
by the differentiated T cells (50), as we have consistently
observed in TCR-transgenic populations activated in vivo in
the presence of CCL25, independently of the immunization
route. In support of this hypothesis, a larger cohort of T cells
activated in vitro by CD3 stimulation—likely to engage the
majority of T cells—upregulated α4β7 expression in the presence
of CCL25.
In conclusion, our investigation provides proof-of-concept
that induction of specific subsets of mucosal T cells can be
achieved by remote immunization, thus paving the way for the
therapeutic manipulation of mucosal immunity.
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